SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Hepatitis
An SI Board Since March 2001
Posts SubjectMarks Bans
312 28 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
237MRK Licenses HCV IL-28B IP to LapCorp Non-exclusively: siliconinvestor.comDewDiligence_on_SI-7/28/2010
236Hope Against Hepatitis C nytimes.com VRTX mentioned prominently.ksuave-7/22/2010
235<b>Who’s Who in All-Oral HCV Programs</b> <i>New table formatDewDiligence_on_SI-6/20/2010
234<b>Who’s Who in All-Oral HCV Programs</b>: siliconinvestor.comDewDiligence_on_SI-6/13/2010
233MRK’s annual R&D Day is tomorrow (Tue): siliconinvestor.comDewDiligence_on_SI-5/10/2010
232Oops—please use this link instead: siliconinvestor.comDewDiligence_on_SI-4/17/2010
231Why HCV Nucleo<u>tides</u> Are Better Than Nucleo<u>sides</DewDiligence_on_SI-4/17/2010
230Re: "Inhibitor-induced structural change in the HCV IRES domain IIa RNA&quotuck-4/5/2010
229Inhibitor-induced structural change in the HCV IRES domain IIa RNA Ryan B. Paulstnsaf-4/5/2010
228Experimental drug is combating hepatitis C in chimps, researchers say The antivitnsaf-12/8/2009
227AEMD is making a presentation on its Hemopurifier tomorrow that should make someksuave-10/29/2009
226GILD’s latest decision may signal the end of the interferon era in HCV: siliconDewDiligence_on_SI-10/20/2009
225HCV: Most Likely to Succeed (IMHO): siliconinvestor.comDewDiligence_on_SI-7/19/2009
224Losartan, an angiotensin-II type 1 receptor blocker, already approved for use agidos-6/5/2009
223The sorry history of TLR agonists in HCV: siliconinvestor.com ANDS has droppedDewDiligence_on_SI-6/5/2009
222GILD dumps ACH-1095—ACHN stunned: siliconinvestor.comDewDiligence_on_SI-5/15/2009
221HCV: Most Likely to Succeed (IMHO) <i>[Updated for data reported at EASL]DewDiligence_on_SI-4/26/2009
220ANA598 from ANDS would seem to out of contention as a serious HCV candidate: siDewDiligence_on_SI-4/23/2009
219Pharmasset cancels hepatitis drug development Pharmasset ends development of leakenhott-4/20/2009
218<b>How to Find the EASL Abstracts of Interest</b> The EASL abstractDewDiligence_on_SI33/19/2009
217MRK’s head of R&D, Peter Kim, just talked up Boceprevir and said absolutely DewDiligence_on_SI-3/9/2009
216Albuferon musings: siliconinvestor.comDewDiligence_on_SI-3/9/2009
215HCV: Most Likely to Succeed (IMHO) <i>Updated entries for IFN-Lambda, ITMDewDiligence_on_SI-1/13/2009
214Info on MRK’s HCV protease inhibitor, MK-7009: Phase-2 trials: siliconinvestor.DewDiligence_on_SI-12/21/2008
213Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon Netnsaf-12/13/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News